Poliovirus therapy induces immune responses against cancer

September 20, 2017, Duke University Medical Center
A modified polio vaccine has shown success in clinical trials at killing cancer cells and destroying tumors. Scientist have learned more details in how this virus engages the bodies' own immune system to attack. Credit: Duke Health

An investigational therapy using modified poliovirus to attack cancer tumors appears to unleash the body's own capacity to fight malignancies by activating an inflammation process that counter's the ability of cancer cells to evade the immune system.

Describing this process in a paper published Sept. 20 in the journal Science Translational Medicine, Duke Cancer Institute researchers provide the first published insight into the workings of a therapy that has shown promise in early clinical trials in patients with recurrent glioblastoma, a lethal form of brain . The modified received a breakthrough therapy designation from the Food and Drug Administration last year, expediting research.

"We have had a general understanding of how the modified poliovirus works, but not the mechanistic details at this level," said co-senior author Matthias Gromeier, M.D., a professor in the Duke Department of Neurosurgery who developed the therapy. "This is hugely important to us. Knowing the steps that occur to generate an will enable us to rationally decide whether and what other therapies make sense in combination with poliovirus to improve patient survival."

Gromeier, with expertise in cancer biology, collaborated with fellow Duke researcher and co-senior author Smita Nair, Ph.D., an immunologist and professor in the Department of Surgery. The research team elucidated how the poliovirus works not only to attack cancer directly, but also to trigger a longer-lasting immune response that appears to inhibit regrowth of the .

Using human melanoma and breast cancer cell lines, and then validating the findings in mouse models, the researchers found that the modified poliovirus therapy starts by attaching to malignant cells, which have an abundance of CD155 protein. The CD155 protein is otherwise known as the poliovirus receptor. The modified virus then begins to attack the , directly killing many, but not all. This releases tumor antigens.

The second phase of assault is more complicated. By killing the cancer cells, the modified poliovirus triggers an alarm within the immune system, alerting the body's defenses to go on the attack.

This appears to occur when the modified poliovirus infects and macrophages. Dendritic cells then present tumor to T cells to launch an immune response. Once the immune system is activated against the poliovirus-infected tumor, the can no longer hide and they remain vulnerable to ongoing immune attack.

"Not only is poliovirus killing tumor cells, it is also infecting the antigen-presenting cells, which allows them to function in such a way that they can now raise a T-cell response that can recognize and infiltrate a tumor," Nair said. "This is an encouraging finding, because it means the poliovirus stimulates an innate inflammatory response."

Nair and Gromeier said further studies will focus on the additional immune activity following exposure to the modified virus.

Explore further: Poliovirus therapy shows survival benefit in early patients

More information: M.C. Brown el al., "Cancer immunotherapy with recombinant poliovirus induces IFN-dominant activation of dendritic cells and tumor antigen–specific CTLs," Science Translational Medicine (2017). stm.sciencemag.org/lookup/doi/ … scitranslmed.aan4220

Related Stories

Poliovirus therapy shows survival benefit in early patients

June 7, 2016
An early group of patients who received a modified form of the poliovirus to treat recurrent glioblastoma brain tumors showed survival improvement over historical controls, according to researchers at the Preston Robert Tisch ...

Can a modified poliovirus fight advanced prostate cancer too?

August 27, 2015
Duke researchers made a big splash in the news last spring when 60 Minutes featured the success of early clinical trials using a modified poliovirus in the fight against a deadly form of brain cancer. Now, with funding from ...

Poliovirus vaccine trial shows early promise for recurrent glioblastoma

May 21, 2013
An attack on glioblastoma brain tumor cells that uses a modified poliovirus is showing encouraging results in an early study to establish the proper dose level, researchers at Duke Cancer Institute report.

Poliovirus study finds that less is more

June 1, 2015
A modified poliovirus therapy that is showing promising results for patients with glioblastoma brain tumors works best at a low dosage, according to the research team at Duke's Preston Robert Tisch Brain Tumor Center where ...

Partnering cells turn off immune attack on pancreatic tumors

July 18, 2017
Two cell types work together to protect pancreatic tumors from destruction by the immune system. But, blocking this partnership may restore the system's ability to attack these same tumor cells.

Adenoviruses and the immune system join forces against cancer

February 16, 2017
Researchers of the Cancer Virotherapy Research Group of Bellvitge Biomedicine Research Institute (IDIBELL), led by Dr. Ramon Alemany, have developed an oncolytic virus capable of redirecting the patient's immune system against ...

Recommended for you

Study finds gut microbiome can control antitumor immune function in liver

May 24, 2018
Scientists have found a connection between bacteria in the gut and antitumor immune responses in the liver. Their study, published May 25 in Science, was led by researchers in the Center for Cancer Research (CCR) at the National ...

Low-fat diet tied to better breast cancer survival

May 24, 2018
(HealthDay)—Breast cancer patients who adopted a low-fat diet were more likely to survive for at least a decade after diagnosis, compared to patients who ate fattier fare, new research shows.

A cascade of immune processes offers insights to triple-negative breast cancer

May 24, 2018
Cancer is crafty. To survive and thrive, tumors find a way of thwarting our body's natural systems.

By forming clots in tumors, immune cell aids lung cancer's spread

May 24, 2018
University of North Carolina Lineberger Comprehensive Cancer Center researchers have found that by helping to form clots within tumors, immune cells that flock to a particular type of lung cancer are actually building a foundation ...

Cancer cells co-opt pain-sensing 'wasabi receptor' to survive oxidative stress

May 24, 2018
Anyone who's taken a bite of a sandwich with too much spicy mustard or a piece of sushi with too much wasabi can attest to the tear-inducing sensation these condiments can cause. These loud warnings to the nervous system ...

Tumor cells evade death through in extremis DNA repair

May 24, 2018
Greater knowledge of the mechanisms that contribute to the survival of tumour cells is key to vanquishing them. The study published today in the journal Cancer Cell, headed by Angel R. Nebreda, ICREA researcher at the Institute ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.